ATLCAR.CD30 Cells

Phase 2Biologic

UUNC Lineberger Comprehensive Cancer Center

ATLCAR.CD30 Cells is one of 49 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Peripheral T-Cell LymphomaRecruiting

Hodgkin DiseaseActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Peripheral T-Cell LymphomaPhase 2

Recruiting

Hodgkin DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

ATLCAR.CD30 Cells

UUNC Lineberger Comprehensive Cancer Center

Phase 2

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

1 10

Antibody-Drug Conjugate

MMBrace Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2037

Phase 1Active, not recruiting

Hodgkin Disease

NCT02663297

Q3 2038

Phase 2Recruiting

Peripheral T-Cell Lymphoma

NCT04083495

Q4 2039

PreclinicalActive, not recruiting

Lymphoma

NCT02690545

Clinical

Trials by Indication[1]

Hodgkin Disease1 trial

Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT02663297·18 enrolled

Peripheral T-Cell Lymphoma1 trial

Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04083495·20 enrolled

Germ Cell Tumor1 trial

Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05634785·2 enrolled

Lymphoma1 trial

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Preclinical·NCT02690545·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ATLCAR.CD30 Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATLCAR.CD30 Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATLCAR.CD30 Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUNC Lineberger Comprehensive Cancer Center

ATLCAR.CD30 Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2037

Q3 2038

Q4 2039

Trials by Indication[1]

Hodgkin Disease1 trial

Peripheral T-Cell Lymphoma1 trial

Germ Cell Tumor1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News